摘要
目的评价右佐匹克隆和佐匹克隆治疗失眠症的疗效和安全性。方法将183例失眠症患者随机分成2组,治疗组92例,对照组91例。治疗组给予右佐匹克隆片3 mg.d-1,睡前服;对照组给予佐匹克隆胶囊7.5~15.0 mg.d-1,睡前服;两组疗程均为15 d,治疗前及治疗第8,15天后采用睡眠障碍量表（SDRS）、临床总体印象量表（CG I）和不良反应量表（TESS）评定临床疗效和不良反应。结果两组治疗结束时SDRS评分较基线均有显著下降（P〈0.01）,治疗组显效率83.7%,对照组显效率81.3%,两组疗效及不良反应比较差异无显著性（P〉0.05）。结论失眠症患者服用右佐匹克隆后睡眠状况明显改善,且不良反应少,患者易于接受。
Objective To evaluate the efficacy and safety of eszopiclone on treating insomnia. Methods 183 patients were randomly divided into the eszopiclone group（n=92） and zopiclone group（n=91）.The treatment group was orally given with eszopiclone 3 mg·d-1,and the control group was given with zopiclone（7.5-15.0 mg·d-1）,respectively for 15 days.Efficacy was assessed with sleep dysfunction rating scale（SDRS） and clinical president the impression meter（CGI）,while safety was judged with treatment emergent symptom scale（TESS）before treatment and 8th and 15th days after treating. Results The scores of SDRS of two groups decreased significantly（P0.01）.The efficacy of the treatment group and control group were 83.7% and 81.3%,respectively.The difference of efficacy and side effects between both groups had no statistic significance（P0.05）. Conclusion Eszopiclone is a safe and effective hypnotic agent.Patients with insomnia have an improved sleep with few side effects by eszopicloneand is compliance to it.
出处
《医药导报》
CAS
2010年第10期1277-1278,共2页
Herald of Medicine
